SD
Stanley Druckenmiller (Duquesne Family Office) disclosed increased in Protagonist Therapeutics Inc
Stanley Druckenmiller (Duquesne Family Office) filed a 13F change in Protagonist Therapeutics Inc (7.4366E+106) on 2026-05-15, covering period end 2026-03-31.
Action
Increased
Capital
$2,884 reported value
Institutional 13F Signals1 evidence source
Why it matters
This signal is anchored to the SEC filing date while retaining the underlying 13F period end.